- Conditions
- Contraception, Pharmacogenomic Drug Interaction
- Interventions
- Desogestrel / Ethinyl Estradiol Pill
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 700 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Contraceptive Usage, Vaginal Epithelial Disruption
- Interventions
- Desogen (ethinyl estradiol and desogestrel), NuvaRing (ethinyl estradiol and etonogestrel)
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Healthy
- Interventions
- DR-1021, Mircette®, Kariva®
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 4
- States / cities
- Lawrenceville, New Jersey • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
- Conditions
- Follicle Development, Ovarian Follicle, Follicle Count, Follicle Size, Oral Contraceptive
- Interventions
- Desogestrel/ethinyl estradiol and ethinyl estradiol, 28-day drospirenone oral contraceptive, 28-day levonorgestrel oral contraceptive
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 206 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Seattle, Washington
- Conditions
- Exercise-related Amenorrhea
- Interventions
- Transdermal 17Beta-estradiol, progesterone, Ethinyl Estradiol + Desogestrel, Sham Comparator
- Drug · Dietary Supplement
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 14 Years to 21 Years · Female only
- Enrollment
- 121 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Infertility
- Interventions
- Oral contraceptive pill and microdose lupron, E2 patch/antagonist
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Other Disorders of Bone Development and Growth
- Interventions
- Combined Oral Contraceptive (COC), Contraceptive Vaginal Ring (CVR)
- Drug
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 18 Years to 25 Years · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2028
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Contraception, Female Contraception
- Interventions
- DR-102
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 2,858 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 52
- States / cities
- Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more
- Conditions
- Bone; Disorder, Development and Growth
- Interventions
- Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring
- Drug
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 18 Years to 30 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Congenital Central Hypoventilation Syndrome
- Interventions
- Desogestrel
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 16 Years to 50 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hemostasis, Oral Contraceptive
- Interventions
- 91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive, 28-day Desogestrel Oral Contraceptive
- Drug
- Lead sponsor
- Teva Women's Health
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 265 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 21
- States / cities
- San Diego, California • Washington D.C., District of Columbia • Miami, Florida + 16 more